Verigraft AB: Funding, Investors & Team (Sep 2026)
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in regenerative medicine by converting donated allogeneic tissue into personalized tissue to prevent transplant rejection. Their unique technology platform involves a combination of decellularization and reconditioning/recellularization processes to individualize patient tissue. Verigraft's technology eliminates the need for lifelong immunosuppression. They aim to provide a life-changing impact to patients while benefiting hospitals, healthcare providers, and society on a global scale. Preclinical development and safety data from large animals have been completed for their personalized tissue-engineered vein (P-TEV) product, with plans for clinical development within the next six months.
Verigraft AB has raised $13.1M across 2 funding rounds on record, the most recent an undisclosed round of $11.9M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Verigraft AB Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Verigraft AB Funding Rounds
Verigraft AB raised $1.2M in an undisclosed round announced in Feb 2025.
1.1 years later, an undisclosed round of $11.9M was announced in Mar 2026.
Verigraft AB Founders and Leadership Team
Contact details for the Verigraft AB team: 1 has a LinkedIn profile.
Start 14-day free trial →Verigraft AB Funding Compared to Other Biotechnology Startups
Verigraft AB's latest round of $11.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Verigraft AB in Biotechnology and Gothenburg
Companies Similar to Verigraft AB
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D…
Verigraft AB Funding FAQs
What does Verigraft AB do?
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in regenerative medicine by converting donated allogeneic tissue into personalized tissue to prevent transplant rejection. Their unique technology platform involves a combination of decellularization and reconditioning/recellularization processes to individualize patient tissue. Verigraft's technology eliminates the need for lifelong immunosuppression. They aim to provide a life-changing impact to patients while benefiting hospitals, healthcare providers, and society on a global scale. Preclinical development and safety data from large animals have been completed for their personalized tissue-engineered vein (P-TEV) product, with plans for clinical development within the next six months.
How much funding has Verigraft AB raised?
Verigraft AB has raised $13.1M across 2 rounds on record. The most recent is an undisclosed round of $11.9M announced in Mar 2026.
When did Verigraft AB last raise funding?
Verigraft AB's most recent funding round on record is an undisclosed round of $11.9M, announced in Mar 2026.
Who founded Verigraft AB?
FundedIQ lists Jan Holgersson (Founder), Petter Bjorquist Verigraft (Founder) at Verigraft AB.
Where is Verigraft AB headquartered?
Verigraft AB is based in Gothenburg, Vastra Gotaland, Sweden.
How many employees does Verigraft AB have?
Verigraft AB is in the 11-50 employee band.
How does Verigraft AB's funding compare to other Biotechnology startups?
Verigraft AB's latest round of $11.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Verigraft AB Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Verigraft AB is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.